We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Teribone Treats Osteoporosis With Noninvasive Systematic Approach
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Teribone Treats Osteoporosis With Noninvasive Systematic Approach
BusinessMedical InnovationsTechnology

Teribone Treats Osteoporosis With Noninvasive Systematic Approach

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

It was announced this week that Zosano Pharma, Inc. (Zosano) and Asahei Kasei Pharma (AKP) formed a collaboration to develop Teribone (teriparatide acetate), a transdermal patch treatment for osteoporosis. Zosano, a biopharmaceutical company and an innovator in the field of drug delivery, develops products using its ZP Patch Technology, a transdermal technology that provides efficient delivery using a noninvasive and painless system.

It was announced this week that Zosano Pharma, Inc. (Zosano) and Asahei Kasei Pharma (AKP) formed a collaboration to develop Teribone (teriparatide acetate), a transdermal patch treatment for osteoporosis. Zosano, a biopharmaceutical company and an innovator in the field of drug delivery, develops products using its ZP Patch Technology, a transdermal technology that provides efficient delivery using a noninvasive and painless system. AKP, a research-based healthcare innovator, has agreed to develop, market and supply Teribone using its human parathyroid hormone, human PTH 1-34, an osteoporosis treatment for patients with high risk of fracture.

Upon the agreement, Teribone uses Zosano’s patented, clinically supported and GMP manufactured ZP Patch Technology to administer AKP’s human PTH (1-34) through the skin. AKP has claimed the exclusive rights to develop and market the transdermal patch product in Japan, Korea, China and Taiwan. Teribone is differentiated through its benefits of self-administration, weekly dosing, room temperature stability, and pain-free delivery without the need for an injection.

“AKP and Zosano have joined their world-class and complementary assets to create what we believe has the opportunity to be the best in class product for bone growth in severe osteoporosis patients” said Gail Schulze, Chief Executive Officer of Zosano. “We believe this relationship will provide a product with superior fracture reduction and enhanced patient compliance compared to the currently available PTH injectables to those patients with a high degree of unmet need.”

More Read

How Digital Is Transforming Employee Healthcare
What Google’s New Adwords Update Means for Medical Marketers
Who Needs a Patient Relationship When You Have an EHR?
Health Start-Ups! – Four Tips for Health IT Start-Ups
Beautiful Healthcare Marketing: Angelina’s Decision

Osteoporosis is a devitalizing disease in which the density and quality of bones are debilitated. An estimated 75 million people are affected in the U.S., Europe and Japan. Bones become fragile and porous with age, and the risk of fracture is greatly increased. Women diagnosed with severe osteoporosis who have had two or more fractures are nine times more likely to fracture than women who have not had a previous fracture.

While most osteoporosis treatments are anti-resorptive compounds, which have been shown to only prevent future bone loss, anabolic compounds like ZP PTH have been shown to stimulate bone growth. During Phase II, all ZP-PTH doses were well tolerated with no systemic adverse events. After such positive results, Zosano’s leading product is ready for Phase III of clinical trials.

 

TAGGED:AKPosteoporosisTeriboneZosano
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Using Asset Management Software in the Healthcare Industry
Technology

10 Benefits of Using Asset Management Software in the Healthcare Industry

April 14, 2024

Why Don’t Hospitals Compete on Quality?

July 23, 2011

Health Care Buzz Today

July 18, 2011

Roche’s Proposed Takeover of Illumina—Game On for Universal DNA Sequencing?

February 4, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?